Filing search / Oncorus, Inc. / "Society"

8-K

EX-99.1

ONCR Oncorus, Inc.

9 Mar 22

Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

7:46am

Presented initial data from ongoing Phase 1 clinical trial of ONCR-177 at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

424B5

ONCR Oncorus, Inc.

19 Nov 21

Prospectus supplement for primary offering

4:41pm

at The Society for Immunotherapy of Cancer’s, or SITC’s Annual Meeting. The data presented at SITC included preliminary findings from Part 1 of our Phase 1

8-K

ONCR Oncorus, Inc.

12 Nov 21

Entry into a Material Definitive Agreement

7:45am

poster presentation discussing the data referred to in the paragraph above at The Society for Immunotherapy of Cancer 's (“SITC”) 36th Anniversary

8-K

EX-99.1

ONCR Oncorus, Inc.

12 Nov 21

Entry into a Material Definitive Agreement

7:45am

at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place November 12-14th in Washington, D.C. and virtually. In the fully

8-K

tjp7uvqmvuly

9 Nov 21

Regulation FD Disclosure

8:10am

8-K

EX-99.1

fk86z7 k7m1uq1xf

9 Nov 21

Regulation FD Disclosure

8:10am

8-K

EX-99.1

g26h nsdui7k9wnu

3 Nov 21

Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates

7:18am

8-K

EX-99.1

15d47 c5w4

21 Jun 21

Oncorus Appoints Eric Rubin, M.D. to its Board of Directors

4:03pm